The Management of Skin Toxicity during Cetuximab Treatment in Advanced Colorectal Cancer: How much does it Cost? A Retrospecive Economic Assessment from a Single-Center Experience

Giuliani, Jacopo; Indelli, Monica; Marzola, Marina; Raisi, Elena; Frassoldati, Antonio

doi:10.1177/030089161209800402

Cited by 9 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…90 Furthermore, a retrospective analysis found that little difference was present in the costs of treatment for a grade 2 (range, 200€–295€) versus grade 3 (range, 159€–234€) rash; however, the cost for grade 1 rash was minimal (no treatments were initiated). 91 Together, these studies suggest that appropriate management to reduce the severity of dermatologic reactions (ie, using preemptive treatment) could translate into substantial cost reductions for the patient, in addition to the other benefits of such an approach.…”

Section: Reviewmentioning

confidence: 99%

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

Lacouture

Anadkat

Jatoi

et al. 2018

Clinical Colorectal Cancer

View full text Add to dashboard Cite

Monoclonal antibody inhibitors of the epidermal growth factor receptor (EGFR) have been shown to improve outcomes for patients with metastatic colorectal cancer (mCRC) without RAS gene mutations. However, treatment with anti-EGFR agents can be associated with toxicities of the skin, nails, hair, and eyes. Because these dermatologic toxicities can result in treatment discontinuation and affect patient quality of life, their management is an important focus when administering anti-EGFR monoclonal antibodies. The present systematic review describes the current data reporting the nature and incidence of, and management and treatment options for, dermatologic toxicities occurring during anti-EGFR treatment of mCRC. A search of the National Library of Medicine PubMed database from January 1, 2009, to August 18, 2016, identified relevant reports discussing dermatologic toxicity management among patients with mCRC receiving anti-EGFR therapy. The studies were grouped by type and rated by level of evidence using the GRADE approach developed by the Agency for Healthcare Research and Quality. Overall, 269 reports were reviewed (nonrandomized trials, n = 120; randomized trials, n = 31; retrospective studies, n = 15; reviews, n = 39). Dermatologic toxicity of any grade occurs in most patients who receive anti-EGFR therapy; approximately 10% to 20% of patients experienced grade 3/4 toxicity. The most common dermatologic toxicities include papulopustular/acneiform rash, xerosis, and pruritus; however, nail changes, hair abnormalities, and ocular conditions also occur. Guidance for managing these toxicities includes the use of inexpensive emollient ointments and moisturizers, avoidance of sun exposure, avoidance of irritants, and the use of short showers. Several studies also found that preemptive treatment was more effective than reactive treatment at limiting the incidence and severity of skin toxicity. With appropriate treatment, the dermatologic toxicities associated with anti-EGFR monoclonal antibody therapy can be managed, minimizing patient discomfort and the need for therapy interruption and/or discontinuation. Additionally, preemptive treatment can reduce dermatologic toxicity severity, ultimately yielding better quality of life.

show abstract

Section: Reviewmentioning

confidence: 99%

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

Lacouture

Anadkat

Jatoi

et al. 2018

Clinical Colorectal Cancer

View full text Add to dashboard Cite

show abstract

“…Two studies looked at all hospital care throughout the care pathway (Laudicella et al, 2016; Macafee & Whynes, 2009). One study focussed on treatment of metastatic and non‐metastatic disease up until the end of life (Mar et al, 2017), whilst another focussed on costs of treating metastatic disease alone (Giuliani et al, 2012). Similarly, one study looked at the cost of surgery alone (Jean‐Claude et al, 2012)and another at the costs from surgery up to three years post‐surgery (Lejeune et al, 2009).…”

Section: Resultsmentioning

confidence: 99%

Health economic studies of colorectal cancer and the contribution of administrative data: A systematic review

et al. 2021

View full text Add to dashboard Cite

Introduction Several forces are contributing to an increase in the number of people living with and surviving colorectal cancer (CRC). However, due to the lack of available data, little is known about the implications of these forces. In recent years, the use of administrative records to inform research has been increasing. The aim of this paper is to investigate the potential contribution that administrative data could have on the health economic research of CRC. Methods To achieve this aim, we conducted a systematic review of the health economic CRC literature published in the United Kingdom and Europe within the last decade (2009–2019). Results Thirty‐seven relevant studies were identified and divided into economic evaluations, cost of illness studies and cost consequence analyses. Conclusions: The use of administrative data, including cancer registry, screening and hospital records, within the health economic research of CRC is commonplace. However, we found that this data often come from regional databases, which reduces the generalisability of results. Further, administrative data appear less able to contribute towards understanding the wider and indirect costs associated with the disease. We explore several ways in which various sources of administrative data could enhance future research in this area.

show abstract

“…Two studies looked at all hospital care throughout the care pathway (Laudi- cella et al, 2016; Macafee and Whynes, 2009). One study focussed on treatment of metastatic and non-metastatic disease up until the end of life Mar et al (2017) whilst another focussed on costs of treating metastatic disease alone (Giuliani et al, 2012). Similarly, one study looked at the cost of surgery alone (Jean-Claude et al, 2012)and another at the costs from surgery up to three years post-surgery (Lejeune et al, 2009).…”

Section: Resultsmentioning

confidence: 99%

“…Similarly, ÓCéilleachair et al (2012) used hospital records from six participating sites to identify patients who would be eligible to take part in interviews for their qualitative analysis of the inter-relationships between the economic and emotional consequences of CRC. Overall, compared to EEs, COI studies are more likely to rely exclusively on administrative data (Corral et al, 2016; Francisci et al, 2013; Giuliani et al, 2012; Laudicella et al, 2016; Lejeune et al, 2009; Macafee and Whynes, 2009; Mar et al, 2017). Finally, almost all of the CC studies use administrative data of some sort.…”

Section: Resultsmentioning

confidence: 99%

Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review

Lemmon

Hanna

Hall

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction: Several forces are contributing to an increase in the number of people living with and surviving colorectal cancer (CRC). However, due to the lack of available data, little is known about those implications. In recent years, the use of administrative records to inform research has been increasing. The aim of this paper is to investigate the potential contribution that administrative data could have on the health economic research of CRC. Methods: To achieve this aim we conducted a systematic review of the health economic CRC literature published in the United Kingdom and Europe within the last decade (2009-2019). Results: Thirty-seven relevant studies were identified and divided into economic evaluations, cost of illness studies and cost consequence analyses. Conclusions: The use of administrative data, including cancer registry, screening and hospital records, within the health economic research of CRC is commonplace. However, we found that this data often comes from regional databases, which reduces the generalisability of results. Further, administrative data appear less able to contribute towards understanding the wider and indirect costs associated with the disease. We have identified several ways in which various sources of administrative data could enhance future research in this area.

show abstract

The Management of Skin Toxicity during Cetuximab Treatment in Advanced Colorectal Cancer: How much does it Cost? A Retrospecive Economic Assessment from a Single-Center Experience

Cited by 9 publications

References 20 publications

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

Health economic studies of colorectal cancer and the contribution of administrative data: A systematic review

Health Economic Studies of Colorectal Cancer and the Contribution of Administrative Data: a Systematic Review

Contact Info

Product

Resources

About